Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene

Cancer Gene Therapy

Volumn 11, Issue 12, 2004, Pages 767-773

  Capiaux, Gina M ^a,b   Budak Alpdogan, Tulin ^b   Alpdogan, Onder ^b   Bornmann, William ^b   Takebe, Naoko ^b,e   Banerjee, Debabrata ^b,f   Maley, Frank ^c   Bertino, Joseph R ^a,b,d,f  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WADSWORTH CENTER   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Dihydrofolate reductase; Gene transfer; Pemetrexed; Thymidylate synthase

Indexed keywords

ANTIMETABOLITE; CISPLATIN; COMPLEMENTARY DNA; DIHYDROFOLATE REDUCTASE; FLUOROURACIL; HYBRID PROTEIN; METHOTREXATE; PEMETREXED; THYMIDYLATE SYNTHASE;

ANIMAL CELL; ARTICLE; BONE MARROW; CELL PROTECTION; CELL STRAIN 3T3; CELL SURVIVAL; COLONY FORMING UNIT GM; CONTROLLED STUDY; FIBROBLAST; FUSION GENE; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; IC 50; MALE; MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; BONE MARROW CELLS; COLONY-FORMING UNITS ASSAY; CYTOPROTECTION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GLUTAMATES; GUANINE; HEMATOPOIETIC STEM CELLS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MICE; MUTATION; NIH 3T3 CELLS; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

ANIMALIA;

EID: 10444284351     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700683     Document Type: Article

References (27)

1. Capiaux GM, Budak-Alpdogan T, Takebe N, et al. Retroviral transduction of a mutant dihydrofolate reductase thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. Human Gene Ther. 2003;14:435-446.
2. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57:1116-1123.
3. Curtin NJ, Hughes AN. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol. 2001;2:298-306.
4. Teicher BA, Chen V, Shih C, et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res. 2000;6:1016-1023.
5. Banerjee D, Bertino JR. Myeloprotection with drug resistance genes. Lancet Oncol. 2002;3:154-158.
6. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating Doxorubicin and CMF regimens in breast cancer with more than 3 positive nodes. 10 year results. JAMA. 1995;273:542-547.
7. Bertino JR. Biomodulation of 5-fluorouracil with antifolates. Semin Oncol. 1997;24:S18-52-S18-56.
8. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. J Clin Oncol. 1989;7:1437-1446.
9. de Mulder PH. The chemotherapy of head and neck cancer. Anticancer Drugs. 1999;10:S33-S37.
10. Markowitz D, Goff S, Band A. Construction and use of a safe and efficient amphotropic packaging celt line. Virology. 1988;167:400-406.
11. Hillcoat BL, Nixon PF, Blakley RL. Effect of substrate decomposition on the spectrophotometric assay of dihydrofolate reductase. Anal Biochem. 1967;21:179-189.
12. Ellis KJ, Morrison JF. Buffers of constant ionic strength for studying pH dependent processes. Methods Enzymol. 1982;87:405-426.
13. Wahba AJ, Friedkin M. Direct spectophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate. J Biol Chem. 1961;236:11-12.
14. Ercikan-Abali EA, Waltham MC, Dicker AP, et al. Variants of human dihydrofolate reductase with substitutions at leucine-22: effect on catalytic and inhibitor binding properties. Mol Pharmacol. 1996;49:430-437.
15. Tong Y, Liu-Chen X, Ercikan-Abali EA, Capiaux GM, Banerjee D, Bertino JR. Isolation and characterization of thymitaq (AG337) and 5-fluoro-2- deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. J Biol Chem. 1998a;273:11611-11618.
16. Williams JW, Morrison JF. The kinetics of reversible tight binding inhibition. Methods Enzymol. 1979;63:437-467.
17. Williams JW, Morrison JF, Duggleby RG. Methotrexate, a high affinity pseudosubstrate of dihydrofolate reductase. Biochemistry. 1979;18:2567-2573.
18. Duggleby RG. Regression analysis of nonlinear Arrhenius plots: an empirical model and a computer program. Comput Biol Med. 1984;14:447-455.
19. Allay JA, Persons DA, Galipeau J, et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med. 1998;4:1136-1143.
20. Ercikan-Abali EA, Mineishi S, et al. Active site-directed double mutants of dihydrofolate reductase. Cancer Res. 1996a;56:4142-4145.
21. Mineishi S, Nakahara S, Takebe N, Banerjee D, Zhao SC, Bertino JR. Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Gene Therapy. 1997;4:570-576.
22. Tong Y, Liu-Chen X, Ericikan-Abali EA, et al. Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. J Biol Chem. 1998b;273:31209-31214.
23. Sauerbrey A, McPherson JP, Ahao S, Banerjee D, Bertino JR. Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside. Hum Gene Ther. 1999;10:2495-2504.
24. Takebe N, Zhao SC, Ural AU, et al. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA. confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD 34+ -enriched peripheral blood progenitor cells. Cancer Gene Ther. 2001;8:966-973.
25. Coutre LA, Mullen CA, Morgan RA. Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression. Hum Gene Ther. 1994;5:667-677.
26. Paz-Ares L, Bezares S, Tabernero JM, Castellanos D, Cortes-Funes H. Review of a promising new agent - pemetrexed disodium. Cancer. 2003;97(Suppl):2056-2063.
27. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644.